Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$258 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8.1
Industry P/E
--
EV/EBITDA
-4.3
Div. Yield
0 %
Debt to Equity
0.6
Book Value
$--
EPS
$-1.7
Face value
--
Shares outstanding
64,561,800
CFO
$-240.81 Mln
EBITDA
$-287.37 Mln
Net Profit
$-274.45 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
| 44.4 | 0.8 | 359.8 | -9.3 | -4.8 | -- | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
| -34.7 | 305.7 | -84.6 | -67.0 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inozyme Pharma Inc (INZY)
|
4.0 | 258.3 | 0.0 | -106.7 | -- | -186.3 | -- | 8.1 |
| 47.0 | 3,540.7 | 219.7 | -253.9 | -120.5 | -53.5 | -- | 8.5 |
Inozyme Pharma, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for rare diseases that affect bone health and blood vessel function. The company's lead product candidate consists of INZ-701, a soluble, recombinant, genetically... engineered, and ENPP1 fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, and calciphylaxis, as well as patients with end-stage kidney disease receiving hemodialysis. It also develops Next Gen ERT for the treatment of ossification of the posterior longitudinal ligament (OPLL); and Gene therapy, a disease of the PPi-Adenosine Pathway. The company has license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. Read more
CEO & Chairman
Dr. Douglas A. Treco Ph.D.
CEO & Chairman
Dr. Douglas A. Treco Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Inozyme Pharma Inc (INZY) is $4.00 (NASDAQ) as of 02-Jul-2025 09:30 EDT. Inozyme Pharma Inc (INZY) has given a return of -4.76% in the last 3 years.
Since, TTM earnings of Inozyme Pharma Inc (INZY) is negative, P/E ratio is not available.
The P/B ratio of Inozyme Pharma Inc (INZY) is 8.12 times as on 02-Jul-2025, a 106 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.71
|
3.01
|
|
2023
|
-3.70
|
1.87
|
|
2022
|
-0.65
|
0.36
|
|
2021
|
-2.86
|
1.48
|
|
2020
|
-6.69
|
2.36
|
The 52-week high and low of Inozyme Pharma Inc (INZY) are Rs 6.24 and Rs 0.72 as of 03-Apr-2026.
Inozyme Pharma Inc (INZY) has a market capitalisation of $ 258 Mln as on 02-Jul-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Inozyme Pharma Inc (INZY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.